For example, a tremor sensor may pass internal testing but fail to correlate with clinician-rated severity in Parkinson’s trials. Without validated comparator data, the signal remains exploratory.

• Analytical Validation: Accuracy, precision, limits of detection (LOD)
• Clinical Validation: Sensitivity, specificity, effect size estimation
• Context of Use: Population, device, endpoint pairing must be clearly defined

Agencies expect robust SOPs and predefined analysis plans. Unvalidated exploratory use often leads to non-acceptance in pivotal trials.

Challenge 2: Data Integrity and Traceability Concerns

Regulatory acceptance hinges on ensuring the data lifecycle—from sensor capture to endpoint reporting—is GxP-compliant. Issues arise in:

• Missing or incomplete data due to device non-compliance
• Undocumented algorithm updates during the trial
• Lack of audit trails for data processing

For example, a heart rate biomarker derived via a wearable must retain a traceable chain of custody. Algorithms used to derive metrics like HRV must be version-controlled and validated. Any update during the trial may compromise data reliability unless thoroughly documented.

Sponsors are encouraged to implement electronic data capture systems that follow 21 CFR Part 11 and GDPR/HIPAA compliance for eSource traceability.

Challenge 3: Unclear Global Regulatory Alignment

Diverging expectations across regulatory agencies can delay or even derail acceptance of digital biomarkers. The FDA has launched initiatives like the Digital Health Software Precertification Program, while the EMA emphasizes Scientific Advice and digital endpoint qualification procedures.

Consider the following table summarizing global differences:

Agency	Position on Digital Biomarkers	Preferred Engagement Route
FDA (US)	Exploratory use encouraged with validation	Pre-IND meeting, CDRH feedback
EMA (EU)	Open to qualification for digital endpoints	Scientific Advice, CHMP digital consultations
PMDA (Japan)	Cautious; prefers conventional endpoints	Clinical Evaluation Consultations

Lack of harmonization means global trials may need region-specific biomarker strategies, requiring more resources and planning.

Challenge 4: Device Classification and Regulatory Oversight

Many digital biomarkers are derived from devices or software that qualify as regulated medical devices. Depending on jurisdiction, classification can differ drastically:

• Software as a Medical Device (SaMD): Algorithms that diagnose or predict conditions
• Wearable Devices: When used in primary endpoints, they may require CE marking or FDA 510(k)
• Combination Products: Sensors integrated with drug delivery mechanisms

For example, an app that calculates seizure risk based on wearable data might be a Class II device in the US, requiring premarket clearance. If the same app is used for exploratory data only, it might not trigger regulatory classification—creating a gray zone that sponsors must clarify early.

Engaging with regulatory authorities early in the protocol design is essential to determine classification impact on timelines and compliance requirements.

Challenge 5: Algorithm Transparency and Version Control

Digital biomarker signals are often derived through proprietary algorithms that process raw sensor data. These “black box” algorithms pose several issues:

• Lack of transparency for regulatory or sponsor review
• Unclear clinical relevance of derived metrics
• Inconsistent outputs across software versions

A best practice is to lock the algorithm version before study start and register it within the protocol or statistical analysis plan (SAP). Any mid-trial algorithm update must be tracked with documented re-validation.

The FDA’s SaMD guidance strongly favors transparency and the ability to audit algorithm logic, especially for endpoints supporting claims.

Challenge 6: Lack of Historical Benchmarks and Comparator Data

Traditional endpoints benefit from decades of comparator datasets, while digital biomarkers often lack a historical control context. This makes it difficult for regulators to assess treatment effect size, variability, or generalizability.

Consider gait speed measured using a smartphone accelerometer. What’s the baseline in a healthy population? How does variability compare with conventional timed walking tests?

To address this, sponsors should:

• Include a comparator arm with both traditional and digital endpoints
• Build internal reference datasets stratified by age, sex, geography
• Use real-world data from other trials to contextualize findings

Best Practices for Regulatory Acceptance

Despite these challenges, several sponsors have successfully navigated the path to digital biomarker acceptance. Key lessons include:

• Engage Early: With FDA or EMA through scientific advice, pre-IND, or innovation offices
• Document Everything: From sensor specs to algorithm source code and version history
• Follow a Modular Validation Strategy: Separate analytical, clinical, and usability modules
• Audit-Ready Data Systems: Ensure end-to-end traceability for every digital data point
• Maintain Cross-Functional Governance: Data science, clinical, QA, and regulatory teams must align

Learn more about validation frameworks for digital endpoints on PharmaGMP.

Conclusion: A New Regulatory Frontier

Regulatory acceptance of digital biomarkers remains a work in progress, but momentum is building. Sponsors who can overcome validation, transparency, and integration hurdles stand to unlock more sensitive, patient-centric, and scalable endpoints.

As regulatory agencies gain more experience and collaborative frameworks evolve, digital biomarkers will transition from innovation to standard practice. Proactive, well-documented engagement will be the key to making that leap.